Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 1998

View Archived Issues

Roche now supplying antiobesity drug in several new markets

Aradigm licenses new aerosol technology from Spanish university

Licensing opportunity from BTG: topically active 5-LO inhibitor for psoriasis

Biogen: Q3 1998 highlights

Licensing opportunity from BTG: 12(R)-HETE formation inhibitor for psoriasis

Dronedarone preclinical data: electrophysiological, hemodynamic and antiarrhythmic effects in dogs

Millennium BioTherapeutics to use Abgenix human antibody technology

Phase I trial for Anergen multiple sclerosis compound demonstrates safety

Oxo Chemie initiates phase III trial of compound for late-stage HIV infection

Yamanouchi applies for approval of oral bisphosphonate in Japan

HMG-CoA reductase inhibitor now under regulatory review in Japan

SkyePharma may acquire DepoTech

Cephems from Zenyaku Kogyo with improved activity compared to flomoxef, vancomycin

Daiichi's new squalene synthase inhibitors

Propionic acid derivatives from Nippon Chemiphar useful for diabetes and related disorders

Antiallergic/antiinflammatory compounds in development at Nikken Chemicals

Potent CRF1 receptor antagonists and their use described by Yoshitomi

Milkhaus successfully completes phase II trial of BPH therapeutic

Knoll terminates verapamil collaboration with Chiroscience; company seeks new partners

U.S. launch announced for Atacand

MorphiDex NDA accepted for FDA review

Overview of studies on SDZ-ASM-981, a potential new gold standard in treating atopic dermatitis

Versed Syrup approved for pediatric sedation

Linoladiol cream: a novel approach to treating acne

Photoprotective efficacy obtained with topical application of vitamin C

Optimal dosing regimen defined for OCT in dose-finding studies

Novel orally active iron chelator presented by Novartis researchers

Linopirdine analogue proves to be more potent neurotransmitter release enhancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...